JPWO2020076809A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020076809A5 JPWO2020076809A5 JP2021518962A JP2021518962A JPWO2020076809A5 JP WO2020076809 A5 JPWO2020076809 A5 JP WO2020076809A5 JP 2021518962 A JP2021518962 A JP 2021518962A JP 2021518962 A JP2021518962 A JP 2021518962A JP WO2020076809 A5 JPWO2020076809 A5 JP WO2020076809A5
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- beta
- medicament
- administered
- ibudilast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 19
- 229960001388 interferon-beta Drugs 0.000 claims 10
- 102000003996 Interferon-beta Human genes 0.000 claims 9
- 108090000467 Interferon-beta Proteins 0.000 claims 9
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 claims 8
- 229960002491 ibudilast Drugs 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 108010005716 Interferon beta-1a Proteins 0.000 claims 3
- 108010005714 Interferon beta-1b Proteins 0.000 claims 3
- 206010053395 Progressive multiple sclerosis Diseases 0.000 claims 3
- 210000004556 brain Anatomy 0.000 claims 3
- 229960004461 interferon beta-1a Drugs 0.000 claims 3
- 229960003161 interferon beta-1b Drugs 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229960003776 glatiramer acetate Drugs 0.000 claims 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862743449P | 2018-10-09 | 2018-10-09 | |
| US62/743,449 | 2018-10-09 | ||
| PCT/US2019/055167 WO2020076809A1 (en) | 2018-10-09 | 2019-10-08 | Combination of ibudilast and interferon-beta and methods of using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022504435A JP2022504435A (ja) | 2022-01-13 |
| JPWO2020076809A5 true JPWO2020076809A5 (enExample) | 2022-10-13 |
Family
ID=68343518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518962A Pending JP2022504435A (ja) | 2018-10-09 | 2019-10-08 | イブジラストとインターフェロン－ベータとの組み合わせ、およびそれを使用する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10946071B2 (enExample) |
| EP (1) | EP3863628B1 (enExample) |
| JP (1) | JP2022504435A (enExample) |
| CN (1) | CN112770748A (enExample) |
| CA (1) | CA3115269A1 (enExample) |
| ES (1) | ES2973119T3 (enExample) |
| WO (1) | WO2020076809A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3226898A1 (en) | 2021-07-26 | 2023-02-02 | Kazuko Matsuda | Ibudilast for preventing eye cancer metastasis |
| US12042485B2 (en) | 2021-10-07 | 2024-07-23 | Medicinova, Inc. | Methods of minimizing cancer metastasis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2231998T3 (es) | 1998-08-10 | 2005-05-16 | Kyorin Pharmaceutical Co., Ltd. | Medicina para la esclerosis multiple. |
| US20060093578A1 (en) * | 2004-11-04 | 2006-05-04 | Kyorin Pharmaceutical Co., Ltd. | Method and composition for treating multiple sclerosis |
| US7534806B2 (en) | 2004-12-06 | 2009-05-19 | Avigen, Inc. | Method for treating neuropathic pain and associated syndromes |
| HRP20120382T1 (hr) * | 2006-05-24 | 2012-06-30 | Merck Serono Sa | Kombinacija davanja interferona-beta i kladribina za liječenje multiple skleroze |
| PT2187882E (pt) | 2007-07-11 | 2013-04-17 | Medicinova Inc | Tratamento de uma doença neurodegenerativa progressiva com ibudilast |
| EP2277515A1 (en) * | 2009-07-10 | 2011-01-26 | Sanofi-Aventis | Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis |
| EP2648732A4 (en) * | 2010-12-07 | 2014-04-30 | Teva Pharma | USE OF LAQUINIMOD TO REDUCE TEMPERATURE, IMPROVE FUNCTIONAL STATUS AND IMPROVE LIFE QUALITY IN PATIENTS WITH MULTIPLE SCLEROSIS |
| DK2675893T3 (en) * | 2011-02-18 | 2019-04-15 | Scripps Research Inst | Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate |
-
2019
- 2019-10-08 JP JP2021518962A patent/JP2022504435A/ja active Pending
- 2019-10-08 EP EP19794366.5A patent/EP3863628B1/en active Active
- 2019-10-08 CN CN201980065787.0A patent/CN112770748A/zh active Pending
- 2019-10-08 ES ES19794366T patent/ES2973119T3/es active Active
- 2019-10-08 US US16/596,278 patent/US10946071B2/en active Active
- 2019-10-08 CA CA3115269A patent/CA3115269A1/en active Pending
- 2019-10-08 WO PCT/US2019/055167 patent/WO2020076809A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023088944A5 (enExample) | ||
| RU2007130700A (ru) | Комбинация соединений метилксантина и стероидов для лечения хронических распираторных заболеваний | |
| JP2017533972A5 (enExample) | ||
| JPWO2019241442A5 (enExample) | ||
| MX2024010637A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| CN107137417B (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JP2025148449A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| JPWO2020257671A5 (enExample) | ||
| JP3616116B2 (ja) | 心臓血管障害の処置のためのａｃｅ阻害剤を配合するｌ−カルニチンまたはアシル−ｌ−カルニチンを含む医薬組成物 | |
| JP2020531527A5 (enExample) | ||
| Roche-Campo et al. | Prone positioning in acute respiratory distress syndrome (ARDS): when and how? | |
| JPWO2020076809A5 (enExample) | ||
| Pascual et al. | Role of lidocaine (lignocaine) in managing status epilepticus. | |
| CN109172550B (zh) | 一种复合麻醉药物 | |
| HUP0402062A2 (hu) | Alkanoil-L-karnitin alkalmazása merevedési zavar kezelésére és ezt tartalmazó gyógyszerkészítmények | |
| Sehgal et al. | Isotretinoin–unapproved indications/uses and dosage: a physician's reference. | |
| Erba et al. | Quantum-First: safety by treatment phase and by age in newly diagnosed (nd) patients (pts) with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) positive acute myeloid leukemia (AML) | |
| WO2013170711A1 (zh) | 一种用于镇痛的药物组合产品 | |
| CN115279354B (zh) | 氯胺酮用于治疗恶病质的用途 | |
| JPH061721A (ja) | 疼痛処置剤、及び疼痛軽減作用増強剤 | |
| CN111374981A (zh) | 匹莫齐特和甲氨蝶呤的药物组合及其应用 | |
| JPWO2023043999A5 (enExample) | ||
| JPWO2020037152A5 (enExample) | ||
| US20250186421A1 (en) | Methods of treating inflammatory and/or allergic disorders with norketotifen |